Core Viewpoint - A class-action lawsuit has been filed against Nutex Health, Inc. alleging fraudulent activities that inflated revenues, resulting in significant investor losses [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Nutex and its partner HaloMD engaged in a scheme to defraud insurance companies by submitting ineligible claims, which were falsely attested to as legitimate [2]. - The allegations were initially brought to light by a report from Blue Orca Capital, which accused HaloMD of a coordinated fraudulent scheme to extract millions from insurance companies [3]. - Following the report, Nutex's stock price fell over 10%, indicating a loss of investor confidence [3]. Group 2: Financial Reporting Issues - The lawsuit also alleges that Nutex overstated its progress in addressing weaknesses in its financial reporting controls, leading to improper accounting of stock-based compensation [4]. - Nutex's delay in filing its Form 10-Q due to accounting adjustments further exacerbated the situation, causing a 16.39% drop in its stock price on August 15, 2025 [5]. Group 3: Company Response and Restatement - On August 21, 2025, Nutex filed a Form 8-K stating that certain prior financial statements would need to be restated due to improper treatment of non-cash obligations [6]. - The company did not adequately rebut the allegations made in the Blue Orca report, only noting that it was not named as a defendant in lawsuits against HaloMD [7]. Group 4: Investor Impact and Recovery Efforts - The class action seeks to recover damages for investors who purchased Nutex securities during the specified class period, alleging that public statements were materially false and misleading [8]. - Hagens Berman is investigating the allegations to determine if Nutex's business model was based on fraudulent practices and whether its financial controls misled investors [9].

SAN FRANCISCO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- A new class-action lawsuit alleges that Nutex, a hospital and healthcare services company, engaged in a fraudulent scheme with a third-party billing firm to inflate its revenues, leading to millions of dollars in losses for investors. The complaint follows a scathing short-seller report that triggered a sharp decline in the company’s stock price and raised questions about its financial disclosures. Hagens Berman urges Nutex investors who suffered substantial ...